首页> 美国卫生研究院文献>BMC Cancer >XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

【2h】

XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

机译：XM02在减少接受多西紫杉醇/阿霉素治疗的乳腺癌患者的第1周期中严重中性粒细胞减少症的持续时间和发热性中性粒细胞减少症的发生率方面优于安慰剂并等效于Neupogen™

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundRecombinant granulocyte colony-stimulating factors (G-CSFs) such as Filgrastim are used to treat chemotherapy-induced neutropenia. We investigated a new G-CSF, XM02, and compared it to Neupogen™ after myelotoxic chemotherapy in breast cancer (BC) patients.

机译：背景技术重组粒细胞集落刺激因子（G-CSFs）（例如Filgrastim）用于治疗化疗引起的中性粒细胞减少。我们研究了一种新的G-CSF XM02，并将其与Neupogen™进行了乳腺癌（BC）患者骨髓毒性化疗后的比较。

著录项

期刊名称 BMC Cancer
作者
A del Giglio; A Eniu; D Ganea-Motan; E Topuzov; H Lubenau;
展开▼
作者单位

展开▼
年(卷),期 2008(8),-1
年度 2008
页码 332
总页数 7
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. XM02 is superior to placebo and equivalent to Neupogen? in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy [J] . A del Giglio, A Eniu, D Ganea-Motan, BMC Cancer . 2008,第1期

机译：XM02是否优于安慰剂并等同于Neupogen？减少接受多西他赛/阿霉素化疗的乳腺癌患者中严重中性粒细胞减少症的持续时间和第一周期中发热性中性粒细胞减少症的发生
2. XM02 is superior to placebo and equivalent to Neupogen? in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy [J] . A del Giglio, A Eniu, D Ganea-Motan, BMC Cancer . 2008,第1期

机译：XM02是否优于安慰剂并等同于Neupogen？减少接受多西他赛/阿霉素化疗的乳腺癌患者中严重中性粒细胞减少症的持续时间和第一周期中发热性中性粒细胞减少症的发生
3. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. [J] . Gatzemeier U, Ciuleanu T, Dediu M, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2009,第6期

机译：XM02是首个生物仿制药G-CSF，在减少接受铂类化学疗法治疗的小细胞或非小细胞肺癌患者中严重中性粒细胞减少症的持续时间和发热性中性粒细胞减少症的发生率方面是安全有效的。
4. The Role of Prophylactic Antibiotics on ANC Value and Fever Duration in Cancer Patients with Post-Chemotherapy Neutropenia Fever [C] . E P Yunita, G J R Subagiyo, S O Wardhani International Seminar on Smart Molecule of Natural Resources . 2020

机译：预防性抗生素对化疗后化学性中性蛋白发热后癌症患者ANC Valys and Heation的作用
5. Effects of primary prophylaxis of neutropenia on outcomes, utilization and expenditures for elderly breast cancer patients receiving chemotherapy. [D] . Rajan, Suja S. 2009

机译：一级预防中性粒细胞减少对老年接受化疗的乳腺癌患者的结局，利用和支出的影响。
6. Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy [O] . Chang Gon Kim, Joohyuk Sohn, Hongjae Chon, 2016

机译：韩国女性乳腺癌患者术前或术后接受阿霉素/环磷酰胺及多西他赛化疗后的发热性中性粒细胞减少症发生率
7. XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy [O] . Topuzov E, Ganea-Motan D, Eniu A, 2008

机译：XM02在减少接受多西紫杉醇/阿霉素治疗的乳腺癌患者的第1周期中严重中性粒细胞减少症的持续时间和发热性中性粒细胞减少症的发生率方面优于安慰剂并等效于Neupogen™
8. Psychological Stress, Neutropenia and Infectious Disease in Patients Receiving Chemotherapy Treatment for Breast Cancer [R] . Bovbjerg, D. 1999

机译：乳腺癌化疗治疗患者的心理应激，中性粒细胞减少和传染病

XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

摘要

著录项

相似文献

相关主题

期刊订阅